Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BOLT Bolt Biotherapeutics, Inc. Common Stock
$6.59 5.10% +0.32
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BOLT stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Bolt Biotherapeutics, Inc. Common Stock (BOLT)

Loading

Key Stats

Market cap. 15.5M
Enterprise value 16.7M
Trailing PE -0.37002801227302
Forward PE -0.3263992
PEG Ratio -0.15002953952161
Enterprise to EBITDA -0.607
Enterprise to revenue 3.558
Price to book MRQ 1.0042671
Price to sales TTM 3.3049426

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 4.7M
EBITDA -27556000
Diluted EPS TTM -16.51
Total Cash (MRQ) 17.6M
Current ratio (MRQ) 2.614
Operating Cash Flow (TTM) -31451000

BOLT trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BOLT News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.